Valuation: InspireMD Inc

Market Cap 33.72M 29.63M 27.3M 25.55M 47.87M 3.18B 48.9M 328M 127M 1.57B 127M 124M 5.45B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 33.72M 29.63M 27.3M 25.55M 47.87M 3.18B 48.9M 328M 127M 1.57B 127M 124M 5.45B EV / Sales 2026 *
3.25x
EV / Sales 2027 * 1.54x
Free-Float
80.17%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 2019-12-31
Director of Finance/CFO 58 2025-06-24
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 2017-06-01
Director/Board Member 68 2013-02-06
Director/Board Member 62 2019-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+5.25%+8.09%-14.78%+12.08% 128B
-0.65%+1.20%+3.41%-8.11% 12.77B
+1.30%+10.51%+42.91%+109.94% 8.48B
-3.88%-6.41%-50.34%-72.89% 3.79B
-0.38%-0.97%+17.98%+37.20% 2.52B
-9.06%+4.50%+229.48%+156.69% 1.55B
-8.75%-13.25%-26.46%-23.39% 1.53B
-2.80%-3.48%-1.78%-22.72% 1.53B
Average -2.37%-0.05%+25.05%+23.60% 19.96B
Weighted average by Cap. +3.91%+6.82%-8.20%+14.78%

Financials

2026 *2027 *
Net sales 10.38M 9.11M 8.4M 7.86M 14.73M 978M 15.04M 101M 39.07M 483M 38.96M 38.11M 1.68B 21.92M 19.25M 17.74M 16.6M 31.11M 2.07B 31.78M 213M 82.53M 1.02B 82.3M 80.49M 3.54B
Net income - -
Net Debt - -
Logo InspireMD Inc
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
-